2024-09-23 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc. is a biotechnology company that develops and commercializes life-saving medicines for serious diseases.

**1. Performance vs. S&P 500 (VOO)**

* **Cumulative Return (REGN):** 117.31%
* **Cumulative Return (VOO):** 132.53%
* **Current Lag:** -15.22%
* **Relative Lag:** 55.6% (Meaning the current lag is at the 55.6th percentile of the historical range between maximum and minimum lag)

**2. Recent Price Movement**

* **Closing Price:** $1145.03
* **5-Day Moving Average:** $1147.38
* **20-Day Moving Average:** $1163.53
* **60-Day Moving Average:** $1117.09

**3. Technical Indicators**

* **RSI:** 39.39 (Suggests the stock is currently in the oversold territory)
* **PPO:** -0.39 (Indicates a bearish trend)
* **Delta_Previous_Relative_Divergence:** -10.81 (Suggests a recent short-term decline in relative strength)
* **Expected_Return:** 17.62% (Represents the potential maximum return over 5 years based on current investment)

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

* **Latest earnings (2024-08-01):** EPS of $13.25 exceeded expectations, with revenue of $3.55B exceeding estimates.

**5. Overall Analysis**

* **Underperformance:** Regeneron Pharmaceuticals has underperformed the S&P 500 in the long term, showing a current lag of -15.22%. 
* **Potential for Recovery:** Recent earnings beat expectations, suggesting potential for a rebound.
* **Oversold Condition:** The RSI is currently in the oversold territory, indicating a possible short-term bounce.
* **Bearish Trend:** The PPO is negative, suggesting a bearish trend, and the recent relative divergence indicates a short-term weakness.
* **Positive Outlook:** Despite the current bearish trend, the expected return of 17.62% over 5 years presents a potential upside for long-term investors.

**Conclusion:** While Regeneron Pharmaceuticals has underperformed the market recently, its strong latest earnings and oversold condition suggest a potential short-term rebound. However, the bearish trend and recent weakness in relative strength warrant caution. Long-term investors may find the expected 17.62% return attractive, but it's essential to monitor the stock closely for signs of a sustained turnaround.
